13-May-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH, said Chris Kirk, CEO and co-founder
12-Nov-2024 3:01 PM CST - Business Wire Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,
17-Oct-2024 7:35 AM CST - Business Wire Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the Board) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC (Concentra) to acquire all of the outstanding shares of common stock of Kezar for cash consideration o
13-May-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH, said Chris Kirk, CEO and co-founder
12-Nov-2024 3:01 PM CST - Business Wire Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,
17-Oct-2024 7:35 AM CST - Business Wire Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the Board) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC (Concentra) to acquire all of the outstanding shares of common stock of Kezar for cash consideration o
